We compared the efficacy and safety of estriol-containing vaginal pessary use with those of oral nitrofurantoin macrocrystal (NM) therapy for preventing urinary tract infection (UTI) in postmenopausal women with recurrent UTI. Over a period of 9 months, 86 women received an estriol-containing vaginal pessary (0.5 mg estriol) twice weekly, and 85 women received NM (100 mg) once daily. We recorded 124 episodes of UTI in women who received estriol-releasing pessaries and 48 episodes of UTI in women treated with NM (P p ). Twenty-eight women (32.6%) who received estriol had no episodes of UTI versus 41 women (48.2%) .0003 in the NM group. There was a significant increase in the number of superficial cells in women who received estriol , whereas in the NM group, no such changes occurred. However, there was no change in the extent of Lactobacillus colonization and in the vaginal pH in women who received estriol. Use of an estriol-containing pessary is less effective than oral NM therapy in the prevention of bacteriuria in postmenopausal women because of its failure to restore the population of lactobacilli and to reduce the vaginal pH in these women.
gonal mucosae, stimulates the proliferation of lactobacilli, and reduces pH, and, as a consequence of these results, reduces colonization with Enterobacteriaceae and prevents bacteriuria [1, 2] . The effectiveness of oral estrogen therapy for preventing UTI in postmenopausal women is less clear and has not been directly studied in a randomized trial.
Long-term, low-dose prophylactic antimicrobial therapy is another well-known method for reducing the incidence of UTI in infection-prone women. Nitrofurantoin is particularly useful for long-term prophylaxis, because the drug is excreted almost entirely in the urine and does not alter the rectal and vaginal flora, and, therefore, it is unlikely to predispose to the emergence of antimicrobial-resistant bacteria [3] .
Given these 2 means of preventing UTI in postmenopausal women (i.e., topical estrogen therapy and lowdose antibiotic therapy), the question arises as to which is more effective and better tolerated. To date, we are not aware of studies comparing the efficacy and safety of prolonged vaginal estriol therapy with those of nitrofurantoin therapy in postmenopausal women with recurrent UTI. Therefore, we undertook this double-blind, double-dummy, randomized trial to determine whether use of an estriol-containing vaginal pessary is more effective and safer than is nitrofurantoin macrocrystal (NM) therapy in reducing the incidence of UTI in postmenopausal women with recurrent UTI.
PATIENTS AND METHODS

Patient population and recruitment.
Postmenopausal women who had been referred to 1 of our 3 outpatient clinics located in northern Israel (in Zvulum, Y.R.; in Linn, R. Roitenberg; in Afula, S.B.) with a history of recurrent UTI (defined as 3 or more confirmed symptomatic episodes of UTI in the last year or at least 2 in the last 6 months) were included in the study.
Exclusion factors were as follows: history of any hormone replacement therapy in the previous year, a known or suspected sex hormone-dependent malignancy or any other active malignancy, vaginal bleeding, an active or recent thromboembolic disease, use of an indwelling catheter, known urinary retention (postvoid volume, 150 mL), long-term (i.e., у2 weeks' duration) receipt of antibiotic therapy in the past 3 months, a major functional or anatomic abnormality of the urogenital tract, diabetes mellitus, severe renal or liver failure, and/or allergy to nitrofurantoin. For women aged !55 years, exclusion factors also included a plasma E 2 level of 1150 pM/L and/or a folliclestimulating hormone level of !40 IU/mL. Enrollment procedures. After providing informed consent, all patients underwent clinical and gynecological examination. A blood sample was obtained for hematologic and chemical testing and for measurement of serum luteinizing hormone and follicle-stimulating hormone levels. A clean-catch midstream urine specimen was collected for urinalysis and culture. The gynecological examination included measurement of vaginal pH, culture of a vaginal swab specimen, and performance of a cervical Papanicolaou (Pap) smear. The sample for the vaginal culture was obtained by rolling a swab across the lateral wall inside the vaginal introitus. Renal ultrasonography that included a postvoiding stage was performed to exclude the diagnosis of any renal abnormality or urinary retention.
Women for whom results of a screening urine culture performed on study entry were found to be negative were divided into 2 groups with a randomization scheme. Women in the "estriol group" received an estriol-containing vaginal pessary daily for 2 weeks and then once every 2 weeks for 9 months together with oral placebo capsules each night during the same period. Women in the "NM group" received a capsule of NM nightly for 9 months together with a placebo vaginal pessary daily for 2 weeks, followed by a placebo pessary every 2 weeks for the remainder of the 9-month period. The study was approved by the Helsinki Committee located at each clinic, and the randomization was performed with a random code stratified by NV Organon.
Follow-up schedule. The women visited the outpatient clinic monthly throughout the study period. At each visit, the patient was asked to report details of UTI symptoms and possible side effects related to the study drug. In addition, a midstream urine sample was obtained for urinalysis and culture. The patients were also asked to visit the clinic whenever possible symptoms of a UTI were present.
At the monthly visits, a gynecological evaluation, which included measurement of vaginal pH, culture of a vaginal swab specimen, and a Pap smear, was performed for the first 1-3 months after initiation of therapy and at the end of the study. The diagnosis of symptomatic UTI was based on the presence of typical clinical symptoms (e.g., dysuria, frequency and urgency, and incontinence), laboratory evidence of pyuria by the leukocyte esterase test (Multistix; Bayer Diagnostics), and a urine culture that yielded at least 10 3 cfu/mL of a uropathogen. Women with symptomatic UTI were treated for 7 days with ciprofloxacin (250 mg b.i.d.) or ofloxacin (200 mg b.i.d.). Women without symptomatic UTI and with bacteriuria (defined as a culture that yielded у10 5 cfu/mL of a pathogen) were not treated.
Microbiological techniques. Midstream urine specimens were collected and cultured with the Hy-Uritest system (Hy Laboratories). All isolates were identified by standard procedures and tested for susceptibility to antimicrobials by the Kirby-Bauer method. Vaginal swab specimens were promptly inoculated onto McConkey agar to isolate aerobic gram-negative strains and onto fresh Rogosa agar to isolate lactobacilli. Lactobacilli were identified by the catalase reaction, detection of b-hemolysis on human bilayer Tween agar, and typical morphological characteristics revealed by Gram staining. The vaginal pH was measured with pH indicator paper (Universal indicator; Merck, Sharp, and Dohme).
Main outcome measurements. The primary efficacy parameter (PEP) was the absence of symptomatic or asymptomatic episodes of bacteriuria during the 9 months of the study. For each group, the cumulative proportion of patients who remained free of UTI was analyzed by the Kaplan-Meier method and tested by the log-rank test. Secondary efficacy parameters included the effect of the study drugs on vaginal cytology, vaginal flora, and pH, and, in addition, side effects attributed to each of the treatments.
To assess whether vaginal atrophy was present, percentages of superficial, intermediate, and parabasal cells were determined by microscopic analysis of the Pap smear. The influence of the hormonal therapy on the vaginal epithelium was measured us- We assessed safety by describing all the adverse events, including serious adverse events and death, and recording the probable relationship between the events and the study drugs. Cessation of therapy because of suspected adverse effects associated with the study drugs was also recorded. For both groups, compliance (expressed as a percentage) with the treatment regimen was defined as the relation between the number of pessaries or capsules administered and the total number allocated.
Statistical analysis. An intent-to-treat (ITT) analysis and a per-protocol analysis were performed. Because no differences between results of the ITT and the per-protocol analyses were seen, the results of the ITT analysis are presented.
The ITT group consisted of all subjects who had at least 1 postbaseline assessment of at least 1 of the PEPs. The x 2 test was used to compare dichotomous and continuous variables. The PEP proportion of women free of bacteriuria was tested by the log-rank test, and the data curves depicted in the figures were constructed by the Kaplan-Meier method. In case an approximate Gaussian distribution could not be assumed, a corresponding nonparametric (Wilcoxon) method was also used.
RESULTS
Patient characteristics.
From June 1996 through January 1999, a total of 171 women were screened; 86 were randomized to the estriol group and 85 to the NM group. Of these patients, 79 in the estriol group and 71 in the NM group were included in the ITT analysis group, and 77 and 62, respectively, completed the entire 9 months of the study. Twenty-seven patients in the estriol group and 23 in the NM group dropped out. Reasons for dropout included adverse events (9 patients in the estriol group and 14 in the NM group), lack of compliance with the treatment regimen (13 and 6, respectively), and intermittent illness (3 and 2, respectively) . The treatment compliance rate (‫ע‬SD) was in the estriol group 93.0% ‫ע‬ 11.1% versus in the NM group. There were no dif-87.0% ‫ע‬ 22.6% ferences in demographic and clinical characteristics between the women in the estriol group and those in the NM group (table 1) .
Assessment of the PEP. We recorded 124 episodes of UTI (85 symptomatic and 39 asymptomatic) in the women who received estriol and 48 episodes (30 symptomatic and 18 asymptomatic) in the women who received NM ( ) P р .0003 (table 2) . The women in the estriol group had 1.6 episodes of UTI per woman and 2 episodes per woman per year, whereas those in the NM group had 0.6 episodes per patient and 0.8 episodes per patient per year.
In addition, there was a significant difference between the 2 groups with respect to the number of women free of bacteriuria. Twenty-eight (32.6%) of the women in the estriol group had no episodes of UTI versus 41 (48.2%) of the women in the , by the log-rank test). Estriol group, women who received estriol-containing pessaries; NM group, women who received nitrofurantoin P ! .0004 macrocrystals (NM).
NM group (
). Kaplan-Meier analysis showed that the P p .01 cumulative proportion of women who remained free of UTI was significantly higher in the NM group ( , by the P p .0004 log-rank test) (figure 1).
Secondary efficacy parameters. Table 3 summarizes, on the basis of the karyopyknotic index and the maturation value, the effect of estriol and NM therapy on vaginal atrophy. Among women in the estriol group, there was a significant increase in the percentage of superficial cells that was attributable to use of the hormone, whereas in women in the NM group, no such changes occurred. However, there was no increase in Lactobacillus colonization in the patients who received estriol, and there was also no significant decrease in the vaginal pH in these women (table 4) .
Adverse events. The percentage of patients with adverse events (36%) and the percentage of those with adverse events that were related to the study drugs (16%) were similar in each group. However, although all adverse events in the women who received estriol were concentrated in the vagina (i.e., itching, burning, vaginal discharge, and metrorrhagia), the adverse events in the women who received NM were more generalized and varied: fever occurred in 5 patients, pneumonitis in 1, thrombocytopenia in 1, urticaria in 3, and gastrointestinal disturbances in 2 (table 5) .
DISCUSSION
The intravaginal use of topical estrogen therapy not only relieves vaginal atrophy and related urogenital symptoms related to menopause, but it also reduces the number of bacteriuric episodes in elderly women with recurrent UTI. In a previous study, we showed that topical estrogen replacement therapy in postmenopausal women restored the population of lactobacilli in the vaginal flora, significantly reduced the vaginal pH, and reduced the extent of vaginal colonization with Enterobacteriaceae [1] . We also demonstrated that the incidence of UTI in women who received estriol-containing vaginal cream was significantly reduced compared with that in women who received a Differences between baseline and months 3 and 6 ( ). P p .07 placebo (0.5 vs. 5.9 episodes per patient per year). Eriksen [2] obtained similar results in a study of treatment with an estradiol-releasing vaginal ring. After 36 weeks of treatment, the cumulative likelihood of remaining free of bacteriuria was 45% for women who used the vaginal ring, compared with 20% for women in the control group [2] . The vaginal pH was also significantly reduced in the estradiol-ring users, and the vaginal epithelial maturation value was significantly improved.
Long-term low-dose antimicrobial prophylaxis has long been used to prevent recurrent UTI in both pre-and postmenopausal women [3] . Several antimicrobial agents have been used, but nitrofurantoin, and NM, in particular, has often been considered the drug of choice, because of its excellent antimicrobial activity against most uropathogens, especially Escherichia coli, and because it does not significantly alter the bacterial flora in the vagina and colon. In addition, receipt of NM does not predispose to the selection of resistant strains or to the presence of Candida vaginitis [4] [5] [6] .
The objective of our study was to compare the efficacy and safety of intravaginal topical estriol therapy with those of NM therapy in postmenopausal women. Our results showed that women who received NM had significantly fewer episodes of symptomatic and asymptomatic bacteriuria than did women who used estriol-containing pessaries; that is, the 79 patients in the estriol group had 124 episodes of bacteriuria, and the 71 women in the NM group had only 48 episodes. This represents rates of 2.0 and 0.8 infections per patient per year, respectively. Moreover, only 35% of the estriol-treated women were free of bacteriuria during the 9 months of follow-up, compared with 58% in the NM group.
However, in our previous study [1] , the incidence of bacteriuria in a similar group of postmenopausal patients who used intravaginally applied estriol cream was 0.5 episodes per woman per year. We decided to use the vaginal pessary in the present study because the intravaginal application of cream is sometimes difficult for older women with poor eyesight, tremor, and other physical limitations. Because the population of women studied in both this and our previous study were very similar, the fact that we recorded a rate of 2 UTI episodes per woman per year among women treated with the pessary versus a rate of 0.5 among those treated with vaginal cream suggests that use of the pessary was less effective than use of the topical vaginal cream for preventing bacteriuria. In spite of the marked estrogenic influence of the estriol-containing pessary in the estriol group, as reflected by the karyopyknotic indexes and maturation values, we observed no changes in either the vaginal flora or vaginal pH. These results are dramatically different from those we observed in our study of the topical estriol cream and strongly suggest that the induced changes in vaginal flora are important for preventing bacteriuria. Several studies of vaginal absorption of estrogen have demonstrated that 0.5 mg of estriol is equally well absorbed and eliminated, whether administered as a cream or released by a pessary [7] . In addition, both routes of administration were shown in previous studies to have equal effects on the vaginal ecology, pH, and restoration of the lactobacilli population, as well as on the improvement of urogenital symptoms related to vaginal atrophy [8] .
The karyopyknotic index and the maturation value are considered reliable cellular indexes for the determination of estrogen activity [9] . Chompootaweep et al. [8] showed an immediate increase in both indexes after use of both a combined contraceptive pill and a conjugated estrogen cream, but, after 4 weeks of therapy, a considerable reduction in these indexes was seen. This decrease may indicate a loss of local effect due to prolonged treatment, with the mucosa becoming refractory when estrogen stimulation is continued for 114 days. We also observed that the maturation value (‫ע‬SD) rose from 11.2 ‫ע‬ before the initiation of treatment to three 15.5 26.1 ‫ע‬ 21.1 months later, but, after 9 months, the maturation value was 19.9 ‫ע‬ 18.1; that is, higher than the value obtained at baseline but considerably lower than the value obtained after 3 months of therapy. Mattsson and Cullberg [10] compared the cytological and clinical response associated with use of either intravaginally applied estriol cream or an estriol-containing vaginal pessary. Both regimens relieved vaginal symptoms and restored the vaginal mucosa, but, after 14 days of treatment, higher values of the karyopyknotic index and the maturation value were calculated for the women receiving vaginal cream.
We conclude that the failure of the vaginal pessary to prevent bacteriuria was related to the fact that it did not modify the vaginal flora and pH, as we observed previously in our study of vaginally applied cream [1] . However, the reasons that the vaginal pessaries did not restore the population of lactobacilli and reduce pH, despite a marked estrogenic effect on the vaginal cytology, are not clear. It is obvious that we do not understand the exact details of the relationship between estrogen activity, as measured by different cytological indexes, and estrogen's ability to restore the population of lactobacilli and reduce pH. These 2 conditions are important for avoiding vaginal colonization with uropathogens and for preventing recurrent UTI. The vaginal epithelium's loss of sensitivity to estrogen during prolonged periods of estrogen-replacement therapy needs to be further investigated. We agree with Mattsson and Cullberg [10] that the different modes of cream application and pessary insertion may explain differences in the resulting estrogen activity in the vagina. The cream was administered by a specially calibrated applicator, and the pessary was inserted manually. It may be difficult for menopausal women to properly insert the pessary manually at the top of the vagina in the periurethral area.
In conclusion, use of the estriol-containing vaginal pessary studied here failed to prevent new episodes of bacteriuria in elderly women with recurrent UTI as effectively as did NM therapy. However, the estriol-releasing pessary did not prevent vaginal colonization with E. coli, restore Lactobacillus colonization, or reduce pH as effectively as did the topical estriol cream we previously studied. Until new studies are performed, prophylactic antimicrobial drugs, such as NM, should be the treatment of choice for recurrent UTI in postmenopausal women.
